Monday , April 28 2025
Home / Mike Norman Economics / Coronavirus: Vaccine hopes boosted as scientists find virus has ‘low shielding’

Coronavirus: Vaccine hopes boosted as scientists find virus has ‘low shielding’

Summary:
Experts say it means there are "fewer obstacles for the immune system to neutralise the virus with antibodies". The world's biggest pharmaceutical company, Johnson & Johnson, told Sky News last month it was confident it had formulated a COVID-19 vaccine and wanted to make available on a not-for-profit basis in 2021. The firm hopes to begin human trials in September, which could mean mass production by early next year. The HIV comparison is significant, as the research was done using special equipment previously provided by a grant from the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery. Coronavirus: Vaccine hopes boosted as scientists find virus has 'low shielding'

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Robert Vienneau writes Austrian Capital Theory And Triple-Switching In The Corn-Tractor Model

Mike Norman writes The Accursed Tariffs — NeilW

Mike Norman writes IRS has agreed to share migrants’ tax information with ICE

Mike Norman writes Trump’s “Liberation Day”: Another PR Gag, or Global Reorientation Turning Point? — Simplicius

Experts say it means there are "fewer obstacles for the immune system to neutralise the virus with antibodies".


Coronavirus: Vaccine hopes boosted as scientists find virus has 'low shielding'


The world's biggest pharmaceutical company, Johnson & Johnson, told Sky News last month it was confident it had formulated a COVID-19 vaccine and wanted to make available on a not-for-profit basis in 2021.

The firm hopes to begin human trials in September, which could mean mass production by early next year.

The HIV comparison is significant, as the research was done using special equipment previously provided by a grant from the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery.

Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *